TAVR/TMVR market projected to reach $8B by 2023

<a ref=“https://www.cardiovascularbusiness.com/topics/structural-congenital-heart-disease/tavrtmvr-market-expected-reach-8b-2023/“>

Apologies if this has already been posted however I find some of the figures quite interesting.

“The global market for transcatheter treatment of the mitral and aortic valves is expected to double over the next five years, according to a new reportfrom BCC Research. The industry analysis projects an increase from $4 billion in 2018 to $8 billion in 2023, at a compound annual growth rate (CAGR) of 14.8 percent.Transcatheter mitral valve repair (TMVR) accounted for just 12 percent of transcatheter aortic or mitral procedures in 2017, according to the report, but are expected to grow faster over the next few years than the more established field of transcatheter aortic valve replacement (TAVR). In 2023, BBC research predicts TMVR will account for 22 percent of the segment while TAVR will claim the other 78 percent—down from 88 percent in 2017.”

If we compare AHZ to 4C:
- 4C currently has a market cap ~2 - 5x that of AHZ ($50-100mil USD vs ~$33mil AUD)
- 4C has recently (over the last few years) managed two decent sized cap raises of $17mil USD and $8mil USD.
- 4C use AHZ’s bioscaffold in their TMVR.
- 4C is pre-revenue and about to commence Early
Feasibility Studies in the US, Canada and Japan.
- 4C is focussed on developing a TMVR (22% of the market above) whilst AHZ is developing a TAVR (78% of market).

Patto shifted the AHZ headquarters to Minnesota ‘the heart’ of the medical device industry to be close to all the major players.

What I’m struggling to understand is why has it been so difficult for Patto to find a decent partner/investor to-date?

From the article above:
“All of the market leaders have focused on merger and acquisition (M&A) activities and have strengthened their market position through acquisitions, minority investments, and financing activities to be in the position to buy targeted early-stage companies,” according to the report.

I guess there is still some hope however why do I feel like I should have invested in 4C Medical rather than AHZ...